Literature DB >> 2542624

Synthesis, posttranslational modifications, and nuclear transport of polyomavirus major capsid protein VP1.

A R Fattaey1, R A Consigli.   

Abstract

Polyomavirus major capsid protein VP1 synthesis was studied in infected primary baby mouse kidney cells. A standard curve of VP1 protein was used to quantitate VP1 in the cytoplasm and nucleus of infected cells during the time course of infection. Polyomavirus VP1 continued to be accumulated in the cytoplasm of the cells until 27 h postinfection, at which time the synthesis of VP1 leveled off. VP1 continued to accumulate in the nucleus of the infected cells throughout the course of infection. The presence of the six isospecies, A to F, of polyomavirus VP1 was also studied to determine the relative quantity of each species during the time course of infection. All six species were found in the cytoplasm and nucleus of infected cells at various times postinfection. However, the relative quantity of each species was different at early as compared with later times of infection. In addition, phosphorylated VP1 was found in isolated polyribosomes of infected cells, suggesting that phosphorylation of VP1 is a cotranslational modification. Examination of the effect of macromolecular synthesis on the transport of VP1 into the nucleus of infected baby mouse kidney cells as well as the rate of its nuclear accumulation during and after protein synthesis inhibition revealed that the continual transport and accumulation of VP1 in the nucleus required protein synthesis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2542624      PMCID: PMC250877     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  A mutant herpesvirus protein leads to a block in nuclear localization of other viral proteins.

Authors:  D M Knipe; J L Smith
Journal:  Mol Cell Biol       Date:  1986-07       Impact factor: 4.272

2.  The carboxyl 35 amino acids of SV40 Vp3 are essential for its nuclear accumulation.

Authors:  E Gharakhanian; J Takahashi; H Kasamatsu
Journal:  Virology       Date:  1987-04       Impact factor: 3.616

3.  Transient inhibition of polyoma virus synthesis by Sendai virus (parainfluenza I). I. Demonstration and nature of the inhibition by inactivated virus.

Authors:  G L Smith; R A Consigli
Journal:  J Virol       Date:  1972-12       Impact factor: 5.103

4.  Rapid equilibrium isopycnic CsC1 gradients.

Authors:  C F Brunk; V Leick
Journal:  Biochim Biophys Acta       Date:  1969-03-18

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Anti-idiotypic antibodies to a polyomavirus monoclonal antibody recognize cell surface components of mouse kidney cells and prevent polyomavirus infection.

Authors:  S J Marriott; D J Roeder; R A Consigli
Journal:  J Virol       Date:  1987-09       Impact factor: 5.103

7.  Polyomavirus major capsid protein VP1 is modified by tyrosine sulfuration.

Authors:  J W Ludlow; R A Consigli
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

8.  Octyl-beta-D-glucopyranoside extracts polyomavirus receptor moieties from the surfaces of mouse kidney cells.

Authors:  S J Marriott; G R Griffith; R A Consigli
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

9.  Expression of polyomavirus virion proteins by a vaccinia virus vector: association of VP1 and VP2 with the nuclear framework.

Authors:  N M Stamatos; S Chakrabarti; B Moss; J D Hare
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

10.  Synthetic peptides containing a region of SV 40 large T-antigen involved in nuclear localization direct the transport of proteins into the nucleus.

Authors:  Y Yoneda; T Arioka; N Imamoto-Sonobe; H Sugawa; Y Shimonishi; T Uchida
Journal:  Exp Cell Res       Date:  1987-06       Impact factor: 3.905

View more
  9 in total

1.  Characterization of the DNA binding properties of polyomavirus capsid protein.

Authors:  D Chang; X Cai; R A Consigli
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

2.  Expression of major capsid protein VP-1 in the absence of viral particles in thymomas induced by murine polyomavirus.

Authors:  N Sanjuan; A Porrás; J Otero; S Perazzo
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

3.  Purification of recombinant budgerigar fledgling disease virus VP1 capsid protein and its ability for in vitro capsid assembly.

Authors:  R E Rodgers; D Chang; X Cai; R A Consigli
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

4.  Expression and purification of recombinant polyomavirus VP2 protein and its interactions with polyomavirus proteins.

Authors:  X Cai; D Chang; S Rottinghaus; R A Consigli
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

5.  Identification of the threonine phosphorylation sites on the polyomavirus major capsid protein VP1: relationship to the activity of middle T antigen.

Authors:  M Li; R L Garcea
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

6.  Mutations in the putative calcium-binding domain of polyomavirus VP1 affect capsid assembly.

Authors:  J I Haynes; D Chang; R A Consigli
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

7.  Production of hepatitis B virus nucleocapsidlike core particles in Xenopus oocytes: assembly occurs mainly in the cytoplasm and does not require the nucleus.

Authors:  S L Zhou; D N Standring
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

8.  Phosphorylation of the budgerigar fledgling disease virus major capsid protein VP1.

Authors:  J I Haynes; R A Consigli
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

9.  Post-translational modifications in capsid proteins of recombinant adeno-associated virus (AAV) 1-rh10 serotypes.

Authors:  Bertin Mary; Shubham Maurya; Sathyathithan Arumugam; Vikas Kumar; Giridhara R Jayandharan
Journal:  FEBS J       Date:  2019-08-01       Impact factor: 5.622

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.